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Synthesis of Some Novel Mannich Bases 
Derived From Allomaltol and Evaluation 
of Their Anticonvulsant Activities 
Mutlu Dilsiz Aytemir*°, Ünsal Çalış*
Introduction
In recent years, antiepileptic drug development has been one of the 
most prominent research areas. Although several new anticonvulsants are 
already in clinical use, some types of seizures are still not adequately trea-
ted with current therapy and have limitations intolerable side effects 1-3.  In 
response to these limitation, the development of new drugs to optimally 
manage seizures has been strongly advocated. Thus the search for new 
anticonvulsant drugs continues to be an active area of investigation in 
medicinal chemistry4-6.
Recent  studies  revealed  that  Mannich  bases  having  piperazine 
groups on the allomaltol (5-hydroxy-2-methyl-4H-pyran-4-one) structure 
showed anticonvulsant activity in the maximal electroshock (MES) and 
subcutaneous Pentylenetetrazole (scMet) screens7. Moreover, structure 
of some compounds were determined by X-Ray analysis 8-10. 
As a continuation of our studies concerning different piperidine de-
rivatives, we aimed to prepare Mannich bases of allomaltol derivatives in 
order to investigate the influence of replacing the piperidine moiety by 
phenylpiperazine derivatives on anticonvulsant activity. The structures 
of the synthesized compounds were confirmed by IR, 1H-NMR, mass spe-
ctra and elemental analysis. Anticonvulsant activities of the compounds 
1-7 were examined by MES and scMet tests. The compounds were sus-
pended in 30 % aqueous of PEG 400 and administered intraperitoneally 
in a volume of 0.01 ml/g at body weight to the mice. Seizure assays and 
Hacettepe University Journal of the Faculty of Pharmacy
Volume 27 / Number 1 / January 2007 / pp. 1-10
Received	 :	 02.03.2007
Revised	 :	 25.07.2007
Accepted	 :	 26.07.2007
*    Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 
06100 Ankara-TURKEY
°    Coresponding author, Tel: 90 312 324 0333 Fax: 90 312 311 4777
    E-mail: mutlud@hacettepe.edu.trHACETTEPE UNIVERSITY JOURNAL OF THE FACULTY OF PHARMACY 2
neurotoxicity were determined according to the phase I tests of the Antie-
pileptic Drug Development (ADD) program protocol which were developed 
by the National Institute of Neurological Disorders and Stroke (NINDS), 
National Institutes of Health (NIH)7, 11-15.
Materials and Methods
Chemistry
All chemicals used in this study were supplied by Merck (Darmstadt, 
Germany)  and  Aldrich  Chemical  Co.  (Steinheim,  Germany).  Melting 
points were determined with a Thomas Hoover Capillary Melting Point 
Apparatus (Philadelphia, PA, USA) and were uncorrected. IR spectra were 
recorded on a Perkin Elmer FT-IR Spectrometer 1720 X (Beaconsfield, 
UK) as KBr disc (γ, cm-1). 1H-NMR spectra were obtained on a Bruker 
AC 80 MHz spectrophotometer and Bruker GMBH DPX-400 MHz High 
Performance Digital FT NMR spectrophotometer (Karlsruhe, Germany) 
using TMS as an internal standard (chemical shift in δ, ppm). Mass spec-
tra were recorded on Agilent 6890 Network GC System and Agilent 5973 
Network Mass Selective Detector. The elemental analyses were performed 
with a Leco CHNS-932 (St. Joseph, MI, USA) at The Scientific & Techno-
logical Research Council of Turkey-Ankara Testing and Analyses Labora-
tory (TÜBİTAK-ATAL). The purity of the compounds was assessed by TLC 
on Kieselgel 60 F254 (Merck, Darmstadt, Germany).
2-(Chloromethyl)-5-hydroxy-4H-pyran-4-one (Chlorokojic acid)
It  was  prepared  by  using  the  procedure  already  described  by 
Yabuta16. 
5-Hydroxy-2-methyl-4H-pyran-4-one (Allomaltol)
Recrystallisation from isopropanol afforded allomaltol as colourless 
plates (14.8 g, 63 %): mp 152-153 oC (lit. value17 153-155 oC). IR (KBr 
disc) 3300-3100 (O-H st), 1640 (C=O st), 1587, 1384 (C=C st), 1223, 1150, 
1050 cm-1 (C-O st).  1H-NMR (DMSO-d6, 60 MHz) δ 2.25 (3H; s; 2-CH3), 
6.10 (1H; s; H3), 6.30-7.15 (broad, 1H, 5-OH), 7.80 (1H; s; H6). 
General synthesis of Mannich bases (Compounds 1-7).
Mannich bases were prepared by the reaction of substituted piperidine 
derivatives (0.01 mol) and allomaltol (0.01 mol) in methanol (15 mL) with 
37% formaline (1 mL). The reaction mixture was stirred vigorously for 15 SYNTHESIS OF SOME NOVEL MANNICH BASES DERIVED FROM ALLOMALTOL AND 
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to 25 min at room temperature. The resulting precipitate was collected 
by filtration and washed cold methanol. The crude product recrystallized 
from appropriate solvents. 
3-Hydroxy-6-methyl-2-(piperidin-1-ylmethyl)-4H-pyran-4-one (1). 
Recrystallization from methanol gave a white powder. IR (KBr disc) 
3300-3100 (O-H st), 1626 (C=O st) and 1460 cm-1 (C=C st).  1H-NMR δ 
(CDCl3, 80 MHz) 1.40-2.00 (6H; m; piperidine), 2.20 (3H; s; 6-CH3), 2.40 
(4H; d; piperidine), 3.50 (2H; s; -CH2-), 6.20 ppm (1H; s; H5).  Anal. Cal. 
for C12H17NO3 M.W.: 223 Cal. C: 64.55H: 7.67 N: 6.27 Found C: 63.98 H: 
7.17 N: 6.02
3-Hydroxy-6-methyl-2-((3-methylpiperidin-1-yl)methyl)-4H-py-
ran-4-one (2).
Recrystallization from ethyl acetate gave a white crystalline solid. IR 
(KBr disc) 3295-3100 (O-H st), 1673 (C=O st) and 1460 cm-1 (C=C st). 1H-
NMR δ (CDCl3, 80 MHz) 0.80 (3H; d; -CH3), 1.40-2.00 (7H; m; piperidine), 
2.20 (3H; s; 6-CH3), 2.40 (2H; d; piperidine), 3.50 (2H; s; -CH2-), 6.20 
ppm (1H; s; H5). GC(MS) m/e 98, 84 (base peak), 70, 56. Anal. Cal. for 
C13H19NO3 M.W.: 237 Cal. C: 65.79 H: 8.07 N: 5.90 Found C: 65.48 H: 
8.39 N: 5.92
3-Hydroxy-6-methyl-2-((4-methylpiperidin-1-yl)methyl)-4H-
pyran-4-one (3).
Recrystallization from chloroform/petroleum ether (40-60 oC) gave a 
white crystalline solid. IR (KBr disc) 3200-2927 (O-H st), 1640 (C=O st) 
and 1459 cm-1 (C=C st). 1H-NMR δ (CDCl3, 80 MHz) 1.00 (3H; d; -CH3), 
1.20-2.00 (5H; m; piperidine), 2.30 (3H; s; 6-CH3), 3.00 (4H; d; piperidine), 
3.70 (2H; s; -CH2-), 6.20 ppm (1H; s; H5). GC(MS) m/e 98 (base peak), 84, 
70, 56. Anal. Cal. for C13H19NO3  M.W.: 237 Cal. C: 65.79 H: 8.07  N: 5.90   
Found C: 65.60 H: 8.45 N: 5.83
 
2-((3,5-Dimethylpiperidin-1-yl)methyl)-3-hydroxy-6-methyl-4H-
pyran-4-one (4).
Recrystallization from ethyl acetate gave a white crystalline solid. IR 
(KBr disc) 3298-2940 (O-H st), 1622 (C=O st) and 1458 cm-1 (C=C st). 1H-
NMR δ (CDCl3, 400 MHz) 0.88 (6H; d; J= 5.71; -CH3), 1.60-1.80 (4H; m; 
piperidine H3’, H4’, H5’), 2.30 (5H; s; 6-CH3 and piperidine H6’), 2.95 (2H; d; HACETTEPE UNIVERSITY JOURNAL OF THE FACULTY OF PHARMACY 4
J= 8.69, piperidine H2’), 3.65 (2H; s; -CH2-), 6.20 ppm (1H; s; H5). GC(MS) 
m/e 113, 98 (base peak), 84, 70, 56. Anal. Cal. for C14H21NO3 M.W.: 251 
Cal. C: 66.90 H: 8.42 N: 5.57 Found C: 67.01 H: 8.25 N: 5.60
 
3-Hydroxy-2-{(4-(4-hydroxyethyl)piperidin-1-yl)methyl}-6-met-
hyl-4H-pyran-4-one (5).
Recrystallization from chloroform/petroleum ether (40-60 oC) gave a 
white crystalline solid. IR (KBr disc) 3408-3000 (O-H st), 1626 (C=O st) 
and 1456 cm-1 (C=C st). 1H-NMR δ (CDCl3, 80 MHz) 1.10-1.90 (5H; m; pi-
peridine), 2.00-2.20 (2H; m; -CH2CH2OH), 2.30 (3H; s; 6-CH3), 3.00 (4H; 
d; piperidine), 3.50-3.90 (4H; m; -CH2- and -CH2CH2OH), 6.10 ppm (1H; 
s; H5). GC(MS) m/e 128, 112, 98, 84, 70, 56 (base peak). Anal. Cal. for 
C14H21NO4.H2O M.W.: 385 Cal. C: 58.93 H: 8.12 N: 4.90 Found C: 58.83 
H: 8.51 N: 4.81
 
3-Hydroxy-2-{(2-(2-hydroxyethyl)piperidin-1-yl)methyl}-6-
methyl-4H-pyran-4-one (6).
Recrystallization from chloroform/petroleum ether (40-60  oC) gave 
a orange crystalline solid. IR (KBr disc) 3242-2937 (O-H st), 1622 (C=O 
st) and 1461 cm-1 (C=C st). 1H-NMR δ (CDCl3, 80 MHz) 2.00-2.25 (7H; m; 
piperidine and 6-CH3), 2.30-2.60 (2H; m; -CH2CH2OH), 3.00-3.60 (7H; 
m; piperidine and -CH2-), 4.00 (2H; t; -CH2CH2OH), 6.20 ppm (1H; s; 
H5). GC(MS) m/e 128, 112, 98, 84, 70, 56 (base peak). Anal. Cal. for 
C14H21NO4.H2O M.W.: 385 Cal. C: 58.93 H: 8.12 N: 4.90 Found C: 59.16 
H: 7.19 N: 4.93
2-((4-Benzylpiperidin-1-yl)methyl)-3-hydroxy-6-methyl-4H-
pyran-4-one (7).
Recrystallization from chloroform/petroleum ether (40-60  oC) gave 
a white crystalline solid. IR (KBr disc) 3100-2879 (O-H st), 1633 (C=O 
st) and 1460 cm-1 (C=C st).  1H-NMR δ (CDCl3, 80 MHz) 1.10-2.00 (5H; 
m;  piperidine),  2.20  (3H;  s;  6-CH3),  2.40  (2H;  d;  -CH2-),  2.85  (4H;  d; 
piperidine), 3.50 (2H; s; -CH2-), 6.10 (1H; s; H5), 6.90-7.30 ppm (5H; m; 
phenyl). GC(MS) m/e 171, 148, 127 (base peak), 112, 98, 85, 56. Anal. 
Cal. for C19H22NO3 M.W.: 312 Cal. C: 73.05 H: 7.09 N: 4.48 Found C: 
72.76 H: 7.40 N: 4.47
Anticonvulsant Activity
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MES and scMet induced seizures. The rotarod toxicity test was perfor-
med for neurological toxicity according to the phase I tests of ADD (Antie-
pileptic Drug Development) program protocol11 which has also been used 
for evaluation in various previous studies7, 14, 15, 17, 18. Stimulator (Grass 
S88, Astro-Med. Inc. Grass Instrument Division, W. Warwick, RI, USA), 
constant  current  unit  (Grass  CCU1A,  Grass  Medical  Instrument,  Qu-
incy, Mass., USA), and corneal electrodes were used for the evaluation 
of anticonvulsant activity against MES test. All synthesized compounds 
were suspended in 30% aqueous of PEG 400 and administered intrape-
ritoneally in a volume of 0.01 ml/g at body weight to the mice. Twelve 
Swiss albino male mice (20 ± 2 g) were used for each compound (mice 
were obtained from the Hacettepe University Animal Farm according to 
the NINDS-ADD program protocol11 and used according to the Hacette-
pe University, ‘Laboratory Animals Ethic Committee’ 17. 04. 2002 date 
2002/ 24-3 number decision). Control animals received 30% aqueous 
PEG 400. Pentylenetetrazole (metrazol) was administered s.c. on the back 
of the neck. The rotarod toxicity test was performed on a 1 inch diameter 
knurled wooden rod; rotating at 6 rpm (the rotarod used in Phase I test 
was made by Hacettepe University Technical Department).
Maximal Electroshock Seizure (MES) test
Maximal electroshock seizures were elicited with a 60-cycle alterna-
ting current of 50 mA intensity (five to seven times that necessary to elicit 
minimal seizures) delivered for 0.2 s via corneal electrodes. A drop of 0.9 
% saline was instilled in each eye prior to application of the electrodes in 
order to prevent the death of the animal. Abolition of the hind limb tonic 
extension component of the seizure was defined as protection.
Subcutaneous Pentylenetetrazole (Metrazol)  (ScMet) test
85 mg/kg of Pentylenetetrazole (produces seizures in more than 95 
% of mice) was administered as a 0.5 % solution subcutaneously into the 
posterior midline. The animal was observed for 30 min. The absence of 
even a threshold seizure (a single episode of clonic spasms of at least 5 s 
duration) was defined as protection.
Neurotoxicity
The rotarod test was used to evaluate the neurotoxicity. The animal 
was placed on a 1 inch diameter knurled wooden rod rotating at 6 rpm. HACETTEPE UNIVERSITY JOURNAL OF THE FACULTY OF PHARMACY 6
Normal mice remain on a rod rotating at this speed indefinitely. Neurolo-
gic toxicity was defined as the failure of the animal to remain on the rod 
for 1 min.
Results and Discussion
Chemistry
Allomaltol was synthesized from commercially available 5-hydroxy-
2-hydroxymethyl-4H-pyran-4-one  (kojic  acid)  in  a  two-step  reaction 
according literature7, 16, 19. Chlorination of the 2-hydroxymethyl moiety of 
kojic acid using neat thionyl chloride afforded 2-chloromethyl-5-hydroxy-
4H-pyran-4-one (chlorokojic acid), with quite significant yield (76%), with 
the ring hydroxyl being unaffected. Allomaltol was produced by reduction 
of chlorokojic acid with zinc dust in concentrated hydrochloric acid7. In 
the hydroxypyran form, only one enolic hydroxyl group is present and the 
position ortho to this hydroxyl group is readily subject to aminomethylation 
in the Mannich reaction at room temperature20, 21. 
In this study, seven new 3-hydroxy-6-methyl-2-substituted 4H-pyran-
4-one derivatives were synthesized as a Mannich bases. Compounds 1-
7 were prepared by the reaction of appropriate substituted piperidine 
derivatives  with  allomaltol  and  formaldehyde  at  room  temperature  in 
methanol (Scheme 1). 
Scheme 1 
Synthesis and structure of the compounds 1-7. SYNTHESIS OF SOME NOVEL MANNICH BASES DERIVED FROM ALLOMALTOL AND 
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The structures of the synthesized compounds 1-7 were confirmed 
by IR,  1H-NMR, mass spectra and elementary analysis. Yields and the 
melting point properties of the synthesized compounds were presented 
in Table I. In the IR spectra, compounds 1-7 have O-H stretching bands 
at 3400-2879 cm–1. All compounds were associated with C=O and C=C 
stretching bands at 1673-1622 and 1461-1456 cm–1 respectively. With 
1H-NMR spectra, H5 protons of the 4H-pyran-4-one ring were found as a 
singlet peak in the region 6.13-7.20 ppm in accordance with literature7. 
6-Methyl-4H-pyran-4-one derivatives showed methyl group protons as a 
singlet at 2.20-2.30 ppm. The methylene group protons of compounds 
1-7 appeared as a singlet at 3.50-3.70 ppm. 
   
TABLE  I
The Structures, Melting Points and Yields of the Synthesized Compounds
O
O
OH
CH3 CH2 R
Compound Number R M. p. (°C) Yield (%)
1 N 150-1 30
2
N
CH3
140-1 56
3 N CH3 146-7 39
4 N
CH3
CH3
154-5 41
5 N C2H4OH 108-9 59
6
N
C2H4OH
107-8 36
7 N CH2 130-1 35HACETTEPE UNIVERSITY JOURNAL OF THE FACULTY OF PHARMACY 8
Anticonvulsant Activity
The anticonvulsant activities of the compounds were initially evalu-
ated against MES and scMet induced seizures using Swiss albino male 
mice (20 ± 2 g). The results are shown in Table II. According to the activity 
studies,  2-((3,5-dimethylpiperidin-1-yl)methyl)-3-hydroxy-6-methyl-4H-
pyran-4-one (compound 4) was determined to be most active against sc-
Met at 100 and 300 mg/kg dose at half an hour. 3-Hydroxy-2-{(4-(4-hyd-
roxy  ethyl)piperidin-1-yl)methyl}-6-methyl-4H-pyran-4-one  (compound 
5) was found to have anticonvulsant activity against scMet seizures at 
300 mg/kg dose at the fourth hour and MES seizures at 300 mg/kg dose 
at half an hour. Compound 7 was protective against scMet at 300 mg/kg 
at the fourth hour. None of the compounds 1, 2, 3 and 6 showed anticon-
vulsant activity. Neurotoxicity was observed in compound 3 which was 
administered to mice at 300 mg/kg dose level.
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Summary
Synthesis of Some Novel Mannich Bases Derived From 
Allomaltol and Evaluation of Their Anticonvulsant Activities
In  this  study,  new  3-hydroxy-6-methyl-2-substituted  4H-pyran-4-
one derivatives were synthesized and their anticonvulsant activities were 
evaluated.  Mannich  bases  were  prepared  by  the  reaction  of  suitable 
piperidine derivatives with allomaltol and formaline. The structure of the 
synthesized compounds was confirmed by IR,  1H-NMR, Mass and elementary 
analysis.  Anticonvulsant  activities  of  the  compounds  were  examined 
by  maximal  electroshock  (MES)  and  subcutaneous  Pentylenetetrazole 
(scMet). Neurotoxicity was determined by rotarod toxicity test. All these 
tests were performed in mice according to procedures of the Antiepileptic 
Drug Development (ADD) program protocol of the National Institutes of 
Health (NIH). According to the activity studies, 2-((3,5-dimethylpiperidin-
1-yl)methyl)-3-hydroxy-6-methyl-4H-pyran-4-one  (compound  4)  was 
determined to be most active against scMet at 100 and 300 mg/kg dose 
at  half  an  hour.  3-Hydroxy-2-{(4-(4-hydroxyethyl)piperidin-1-yl)methyl}-
6-methyl-4H-pyran-4-one  (compound  5)  and  2-((4-benzylpiperidin-1-
yl)methyl)-3-hydroxy-6-methyl-4H-pyran-4-one (compound 7) were found 
to have anticonvulsant activity against scMet seizures at 300 mg/kg dose. 
Only compound 5 was shown to be protective against MES at 300 mg/kg 
dose in this series.        SYNTHESIS OF SOME NOVEL MANNICH BASES DERIVED FROM ALLOMALTOL AND 
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Key words:  Allomaltol, 3-hydroxy-6-methyl-2-substituted 4H-pyran-
4-one derivatives, Mannich bases, anticonvulsant activity
Özet
Allomaltolden Türetilen Bazı Yeni Mannich Bazlarının Sentezi 
ve Antikonvülsan Aktivitelerinin Değerlendirilmesi
Bu  çalışmada,  yeni  3-hidroksi-6-metil-2-sübstitüe  4H-piran-4-on 
türevleri sentezlenmiş ve antikonvülsan aktivitelerini değerlendirilmiştir. 
Mannich bazları, uygun piperidin türevleri ile allomaltol ve formaldehitin 
reaksiyona  sokulması  sonucu  hazırlanmıştır.  Sentezlenen  bileşiklerin 
yapıları  IR,  1H-NMR,  Mass  ve  elementel  analiz  ile  aydınlatılmıştır. 
Maksimal elektroşok (MES) ve subkutan pentilentetrazol (scMet) testleri 
ile bileşiklerin antikonvülsan aktiviteleri araştırılmıştır. Rotarod toksisite 
testi ile nörotoksisiteleri saptanmıştır. Bütün bu testler, farelerde Amerika 
Ulusal  Sağlık  Enstitüsü’nün  (NIH)  Antiepileptik  İlaç  Geliştirme  (ADD) 
program protokolüne göre yapılmıştır. Aktivite çalışmasına göre, 2-((3,5-
dimetilpiperidin-1-ilmetil)-3-hidroksi-6-metil-4H-piran-4-on  (4)  bileşiği 
scMet nöbetlerine karşı yarım saatde 100 ve 300 mg/kg dozlarda en aktif 
bileşik olduğu saptanmıştır. 3-Hidroksi-2-{(4-(4-hidroksietil)piperidin-1-
il)metil}-6-metil-4H-piran-4-on  (5)  ve  2-((4-benzilpiperidin-1-il)metil)-3-
hidroksi-6-metil-4H-piran-4-on  (7)  bileşikleri  scMet  nöbetlerine  karşı 
300 mg/kg dozda antikonvülsan aktiviteye sahip olduğu bulunmuştur. 
Bu seride sadece bileşik 5’in, 300 mg/kg dozda MES’e karşı koruyucu 
özellik göstermiştir. 
Anahtar  Kelimeler:    Allomaltol,  3-hidroksi-6-metil-2-sübstitüe-4H-
piran-4-on türevleri, Mannich bazları, antikonvülsan aktivite
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